Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study compares promising drug to standard care for Hard-to-Treat cancers

NCT ID NCT06973161

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This study looks at how well the drug T-DXd works compared to usual treatments for people with several types of advanced cancers that have high levels of a protein called HER2. Researchers used data from past trials and real-world medical records to compare survival rates. The goal is to see if T-DXd offers a better chance at living longer for these patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Spartanburg, South Carolina, 29303, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Vienna, Austria

  • Research Site

    Liège, Belgium

  • Research Site

    London, Ontario, N6A 5A5, Canada

  • Research Site

    Olomouc, Czechia

  • Research Site

    Copenhagen, Denmark

  • Research Site

    Caen, France

  • Research Site

    Lille, France

  • Research Site

    Marseille, France

  • Research Site

    Nice, France

  • Research Site

    Paris, France

  • Research Site

    Saint-Herblain, France

  • Research Site

    Berlin, Germany

  • Research Site

    Essen, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Heidelberg, Germany

  • Research Site

    Würzburg, Germany

  • Research Site

    Meldola, Italy

  • Research Site

    Rome, Italy

  • Research Site

    Porto, Portugal

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Pamplona, Spain

  • Research Site

    Valencia, Spain

  • Research Site

    Leeds, United Kingdom

  • Research Site

    London, United Kingdom

Conditions

Explore the condition pages connected to this study.